BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Empaveli (Pegcetacoplan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Empaveli (Pegcetacoplan)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07495722-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Empaveli (Pegcetacoplan): Phase 1 readout est. (NCT07495722)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 1.\nStudy: Safely Quenching Co
 mplement in Stroke Survivors\nEstimated primary completion: April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pegcetacoplan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07495722
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05809531-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT05809531)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: An Open-Label\, Non
 randomized\, Multicenter Extension Study to Evaluate the Long-term Safety 
 and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Im
 mune-Complex Membranoproliferative Glomerulonephritis\nEstimated primary c
 ompletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05809531
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214298-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280216
DTEND;VALUE=DATE:20280217
SUMMARY:Empaveli (Pegcetacoplan): Phase 1/2 readout est. (NCT07214298)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 1/2.\nStudy: Pegcetacoplan in 
 Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancr
 eatic Ductal Adenocarcinoma\nEstimated primary completion: 16 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacoplan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07214298
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04919629-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Empaveli (Pegcetacoplan): Phase 2 readout est. (NCT04919629)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 2.\nStudy: APL-2 and Pembroliz
 umab Versus APL-2\, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone
  for the Treatment of Recurrent Ovarian\, Fallopian Tube\, or Primary Peri
 toneal Cancer and Malignant Effusion\nEstimated primary completion: 30 Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacopla
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 919629
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901936-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Empaveli (Pegcetacoplan): Phase 2 readout est. (NCT04901936)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 2\, Paroxysmal Nocturnal Hemog
 lobinuria.\nStudy: A Study of Pegcetacoplan in Pediatric Patients With Par
 oxysmal Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacop
 lan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04901936
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898774-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20310117
DTEND;VALUE=DATE:20310118
SUMMARY:Empaveli (Pegcetacoplan): Phase 3 readout est. (NCT07898774)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 3.\nStudy: A Study to Assess t
 he Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3
 G or Primary IC-MPGN in Kidney Transplant Recipients\nEstimated primary co
 mpletion: 17 January 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pegcetacoplan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07898774
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746895-907@assetmemo.bio
DTSTAMP:20261121T004042Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Empaveli (Pegcetacoplan): Phase 4 readout est. (NCT07746895)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 4.\nStudy: Real-World Effectiv
 eness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-
 Country Study\nEstimated primary completion: 31 December 2031. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pegcetacoplan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07746895
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
